$Crystals of HIV-1 reverse transcriptase diffracting to 2.2 A resolution.$

Crystals of HIV-1 reverse transcriptase diffracting to 2.2 A resolution.

Reverse transcriptase (RT) from the human immunodeficiency virus type 1 has been crystallized in four closely related forms, the best of which diffract X-rays to 2.2 A resolution. The RT was crystallized as a complex with a non-nucleoside inhibitor, either nevirapine or a nevirapine analogue. Crysta...

Bibliográfalaš dieđut
Váldodahkkit:	Stammers, D, Somers, DO, Ross, C, Kirby, I, Ray, P, Wilson, J, Norman, M, Ren, J, Esnouf, R, Garman, E
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	1994

Geahča maid

Continuous and discontinuous changes in the unit cell of HIV-1 reverse transcriptase crystals on dehydration.
Dahkki: Esnouf, R, et al.
Almmustuhtton: (1998)

Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives.
Dahkki: Ren, J, et al.
Almmustuhtton: (1998)

Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors.
Dahkki: Esnouf, R, et al.
Almmustuhtton: (1995)

THE GROWTH AND CHARACTERIZATION OF CRYSTALS OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) REVERSE-TRANSCRIPTASE
Dahkki: Jones, E, et al.
Almmustuhtton: (1993)

The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design.
Dahkki: Ren, J, et al.
Almmustuhtton: (1995)

Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.
Dahkki: Ren, J, et al.
Almmustuhtton: (2002)

3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes.
Dahkki: Ren, J, et al.
Almmustuhtton: (1998)

Cloning, expression, purification, and crystallisation of HIV-2 reverse transcriptase.
Dahkki: Bird, L, et al.
Almmustuhtton: (2003)

Crystallographic analysis of the binding modes of thiazoloisoindolinone non-nucleoside inhibitors to HIV-1 reverse transcriptase and comparison with modeling studies.
Dahkki: Ren, J, et al.
Almmustuhtton: (1999)

Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analyses.
Dahkki: Ren, J, et al.
Almmustuhtton: (2000)

Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor.
Dahkki: Esnouf, R, et al.
Almmustuhtton: (1997)

STRUCTURAL STUDIES ON HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE
Dahkki: Stammers, D, et al.
Almmustuhtton: (1990)

Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase.
Dahkki: Pelemans, H, et al.
Almmustuhtton: (1998)

HIV-1 reverse transcriptase: crystallization and analysis of domain structure by limited proteolysis.
Dahkki: Lowe, D, et al.
Almmustuhtton: (1988)

Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
Dahkki: Ren, J, et al.
Almmustuhtton: (2008)

HIV reverse transcriptase structures: designing new inhibitors and understanding mechanisms of drug resistance.
Dahkki: Ren, J, et al.
Almmustuhtton: (2005)

Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.
Dahkki: Hopkins, A, et al.
Almmustuhtton: (1996)

Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine.
Dahkki: Lennerstrand, J, et al.
Almmustuhtton: (2001)

Formation of heterodimers of human-immunodeficiency-virus-type-1 reverse transcriptase by recombination of separately purified subunits.
Dahkki: Stammers, D, et al.
Almmustuhtton: (1992)

Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors.
Dahkki: Ren, J, et al.
Almmustuhtton: (2004)

Biaryl acids: novel non-nucleoside inhibitors of HIV reverse transcriptase types 1 and 2.
Dahkki: Milton, J, et al.
Almmustuhtton: (1998)

High resolution structures of HIV-1 RT from four RT-inhibitor complexes.
Dahkki: Ren, J, et al.
Almmustuhtton: (1995)

A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance.
Dahkki: Harrigan, P, et al.
Almmustuhtton: (2002)

A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781.
Dahkki: Balzarini, J, et al.
Almmustuhtton: (1998)

Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives.
Dahkki: Esnouf, R, et al.
Almmustuhtton: (1997)

2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Dahkki: Chan, J, et al.
Almmustuhtton: (2001)

Reverse transcriptase activity in psoriatic lesions: effects of reverse transcriptase inhibitors on keratinocyte proliferation and differentiation
Dahkki: Bonté Frédéric, et al.
Almmustuhtton: (2009-09-01)

Isolation and characterization of monoclonal antibodies raised against the reverse transcriptase of human immunodeficiency virus type 2 and cross-reactivity with that of type 1.
Dahkki: Snowden, W, et al.
Almmustuhtton: (1993)

Crystal structures of Zidovudine- or Lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215.
Dahkki: Chamberlain, P, et al.
Almmustuhtton: (2002)

Inhibition of HIV-1 reverse transcriptase by defined template/primer DNA oligonucleotides: effect of template length and binding characteristics.
Dahkki: Idriss, H, et al.
Almmustuhtton: (1994)

Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors.
Dahkki: Auwerx, J, et al.
Almmustuhtton: (2004)

Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.
Dahkki: Ren, J, et al.
Almmustuhtton: (2000)

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
Dahkki: Hopkins, A, et al.
Almmustuhtton: (2004)

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
Dahkki: Freeman, G, et al.
Almmustuhtton: (2004)

Background Activity of Reverse Transcriptases
Dahkki: Angelica V. Timofeeva, et al.
Almmustuhtton: (2001-01-01)

A reverse transcriptase ribozyme
Dahkki: Biswajit Samanta, et al.
Almmustuhtton: (2017-09-01)

Rapid purification and characterisation of HIV-1 reverse transcriptase and RNaseH engineered to incorporate a C-terminal tripeptide alpha-tubulin epitope.
Dahkki: Stammers, D, et al.
Almmustuhtton: (1991)

Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants.
Dahkki: Lennerstrand, J, et al.
Almmustuhtton: (2001)

Targeting the Structural Maturation Pathway of HIV-1 Reverse Transcriptase
Dahkki: Thomas W. Kirby, et al.
Almmustuhtton: (2023-11-01)

Crystal structures of HIV-1 reverse transcriptase mutated at codons 100, 106 and 108 show nevirapine resistance is mediated via perturbation of interactions with Tyr181 or Tyr188
Dahkki: Stammers, D, et al.
Almmustuhtton: (2002)